Catalyst Dossier · compiled by CeliA 🧫

CASTLE BIOSCIENCES INC (CSTL)

Services-Medical Laboratories · market cap $641M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-03Earningsimp 5/10

Pipeline

Asset	Phase	Indication
D-Fi	Phase 3	Dystrophic Epidermolysis Bullosa
Autologous Human Fibroblast (azficel-T)	Phase 3	Bilateral Nasolabial Fold Wrinkles
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)	Phase 3	Recessive Dystrophic Epidermolysis Bullosa
Azficel-T (autologous fibroblasts)	Phase 2	Dysphonia Resulting From Vocal Fold Scarring
Autologous Human Fibroblasts (azficel-T)	Phase 3	Acne Scarring of the Face
diacerein 1% ointment	Phase 2	Epidermolysis Bullosa

Price & technical context

3-month

+0.7%

6-month

-37.1%

12-month

+21.0%

52-wk range

$14.65–$43.04

vs 50-day MA

+13.6%

vs 200-day MA

-13.9%

Realized vol

62.7%

Max drawdown

-57.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CSTL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.